|1.||McArthur, Justin C: 2 articles (06/2003 - 02/2002)|
|2.||De Clercq, Erik: 1 article (07/2015)|
|3.||Marquie-Beck, J A: 1 article (10/2008)|
|4.||Gibson, S A: 1 article (10/2008)|
|5.||Letendre, S L: 1 article (10/2008)|
|6.||Hung, C F: 1 article (10/2008)|
|7.||Vaida, F: 1 article (10/2008)|
|8.||Lonergan, J T: 1 article (10/2008)|
|9.||Ellis, R J: 1 article (10/2008)|
|10.||Lactic Acidosis International Study Group: 1 article (11/2007)|
12/01/1987 - "These results suggest that dideoxynucleosides may be less effective in vivo for HIV-2 infection and that a broader range of clinical isolates of human retroviruses should be examined for drug susceptibility in vitro."
04/01/1999 - "Lamivudine or 3TC, the (-) eniantiomer of 2'-deoxy-3'-thiacytidine, is a prototype of a novel class of levogyre dideoxynucleosides analogues used in treatment of HIV and HBV infection. "
08/01/1990 - "In the present set of experiments, we studied the interaction between certain agents which increase the infection of monocyte/macrophages (M/M) by HIV and two groups of anti-HIV agents: dideoxynucleosides and specific inhibitors of gp120-CD4 binding. "
09/01/1990 - "Dideoxynucleosides (zidovudine[AZT], dideoxycytidine[ddC], and dideoxyinosine[ddI]) are promising new agents for the management of human immunodeficiency virus type 1 (HIV-1) infections. "
|2.||Peripheral Nervous System Diseases (PNS Diseases)
|3.||Acquired Immunodeficiency Syndrome (AIDS)
08/01/1992 - "Our toxicity data from canine bone marrow progenitor cells paralleled the clinical hematotoxicity profiles of these dideoxynucleosides in AIDS patients and suggest that the myelotoxicity of a nucleoside analog is related to its ability to permeate the progenitor cells in question. "
01/01/1989 - "Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides."
04/01/1988 - "We have previously shown that 2',3'-dideoxynucleosides and their derivatives are potent inhibitors of the infectivity and cytopathic effect mediated by human immunodeficiency virus type-1 (HIV-1), the causative agent of acquired immunodeficiency syndrome (AIDS). "
04/01/1987 - "Certain dideoxynucleosides have been shown to markedly inhibit the infectivity of human T-lymphotropic virus type III/lymphadenopathy-associated virus, the causative agent of acquired immunodeficiency syndrome (AIDS). "
09/01/1990 - "[Antiviral chemotherapy for AIDS: dideoxynucleosides and clinical application]."
|4.||HIV Infections (HIV Infection)
11/01/1992 - "[Efficacy and tolerance of dideoxynucleosides in HIV infection]."
06/01/2003 - "The combined use of dideoxynucleosides, in association with immune-mediated mechanisms triggered by HIV infection, are critical in the development of distal sensory polyneuropathy. "
10/01/1991 - "Antiviral therapy of human immunodeficiency virus (HIV) infection is currently based on inhibition of reverse transcriptase by dideoxynucleosides, such as azidothymidine. "
05/21/1990 - "The dideoxynucleosides 3'-azido-3'-deoxythymidine (zidovudine, AZT) and 2',3'-dideoxycytidine (ddC) are potent inhibitors of human immunodeficiency virus (HIV) in vitro and improve surrogate measures of HIV infection in vivo. "
10/01/1992 - "Many of the dideoxynucleosides effective systemically in the treatment of HIV infections, such as 2',3'-dideoxyinosine (ddI), exhibit limited penetration into the CNS and limited or variable effectiveness in reversing the symptoms of AIDS dementia. "
11/30/2007 - "Hyperlactataemia/lactic acidosis was associated with exposure to dideoxynucleosides, female gender, advanced immunosuppression and possibly ethnicity. "
05/01/2001 - "Like other antihuman immunodeficiency virus dideoxynucleosides, stavudine may occasionally induce lactic acidosis and perhaps lipodystrophy in metabolically or genetically susceptible patients. "
|5.||Mitochondrial DNA (mtDNA)
|6.||Anti-HIV Agents (AIDS Drugs)
|8.||Reverse Transcriptase Inhibitors
|9.||Interferon-alpha (Interferon Alfa)
|1.||Drug Therapy (Chemotherapy)